Analysis of treatment outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis on rituximab therapy.
Tsvetelina YonevaYana ZdravkovaGeorgi KotovEkaterina Ivanova TodorovaGeorgi Hristov VasilevRasho RashkovIvan SheytanovPublished in: Archives of rheumatology (2022)
Rituximab is an efficient and safe therapeutic option in patients with AAV who are difficult to treat, have insufficient response, or have not tolerated other treatments.